Lung Cancer Clinical Trials
A Phase 3 trial comparing the study drug ASP8273 to erlotinib or gefitinib in previously untreated patients diagnosed with Stage IIIB/IV non-small cell lung cancer tumors that have EGFR-activating mutations (Protocol 8273-CL-0302).
- This study is open to patients who are newly diagnosed or have recurrent disease.
- Patients must have locally advanced, metastatic non-small cell lung cancer that cannot be surgically removed.
- Patients must not have not received treatment targeting EGFR mutations.
- If patients have received treatment before, or during chemotherapy (“neoadjuvant” or “adjuvant”), this must be completed 6 months before starting the study.
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC.
A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
This is a Phase 1 and 2 study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) agent. The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered HS-10296.
A Phase 2, Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment with a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating EGFR mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who have either BM or LM at initial presentation.
SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel or pemetrexed is more effective than docetaxel or pemetrexed alone in regards to OS in patients with heregulin-positive non-small cell lung cancer (NSCLC) that is histologically classified as adenocarcinoma.
A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
Schedule a Consultation Today!
Your health is important, and we welcome the opportunity to help you heal.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or use our interactive Online Appointment Request Form.